Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 69

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 69
---
0252024(unaudited)(unaudited)Net earnings$22,499 $19,916 $10,672 $20,040 Other comprehensive gain (loss)Unrealized gain (loss) on marketable securities, net of tax(41)162 (11)221 Other comprehensive gain (loss)(41)162 (11)221 Comprehensive earnings$22,458 $20,078 $10,661 $20,261 

See accompanying notes.

5

Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Changes in Stockholders' Equity 

(unaudited, in thousands, except share data)

jCommon StockAdditional Paid-in CapitalAccumulated OtherComprehensiveEarnings (Loss)RetainedEarningsTotalStockholders'EquitySharesAmountBalance, December 31, 202455,743,095 $56 $479,440 $(189)$556,426 $1,035,733 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 8,068 — — 8,068 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld246,153 — (1,299)— — (1,299)Net loss— — — — (11,827)(11,827)Unrealized gain on marketable securities, net of tax— — — 30 — 30 Balance, March 31, 202555,989,248 $56 $486,209 $(159)$544,599 $1,030,705 Share-based compensation expense related to employee stock purchase plan and share-based awards— 7,507 — — 7,507 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld130,112 — 3,230 — — 3,230 Net earnings— — — — 22,499 22,499 Unrealized loss on marketable securities, net of tax— — — (41)— (41)Balance, June 30, 202556,119,360 56 496,946 (200)567,098 1,063,900 

See accompanying notes.

6

Sup